Cardiovascular Therapies Targeting Left Atrial Appendage

Simple item page
dc.contributor.authorTuragam, Mohit K.
dc.contributor.authorVelagapudi, Poonam
dc.contributor.authorKar, Saibal
dc.contributor.authorHolmes, David Richard D.R.
dc.contributor.authorReddy, Vivek Y.
dc.contributor.authorRefaat, Marwan M.
dc.contributor.authorDi Biase, Luigi
dc.contributor.authorAl-Ahmed, Amin
dc.contributor.authorChung, Mina K.
dc.contributor.authorLewalter, Thorsten
dc.contributor.authorEdgerton, James R.
dc.contributor.authorCox, James L.
dc.contributor.authorFisher, John D.
dc.contributor.authorNatale, Andrea
dc.contributor.authorLakkireddy, Dhanunjaya R.
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:53:38Z
dc.date.available2025-01-24T11:53:38Z
dc.date.issued2018
dc.description.abstractLeft atrial appendage (LAA) closure has evolved as an effective strategy for stroke prevention in patients with atrial fibrillation who are considered suitable for oral anticoagulation. There is strong evidence based on randomized clinical trials with 1 percutaneous device, as well as a large registry experience with several devices, regarding the safety and efficacy of this strategy. In addition, there is encouraging data regarding the effect of epicardial LAA closure on decreasing arrhythmia burden and improvements in systemic homeostasis by neurohormonal modulation. However, there are several unresolved issues regarding optimal patient selection, device selection, management of periprocedural complications including device-related thrombus, residual leaks, and pericarditis. In this review, we summarize the rationale, evidence, optimal patient selection, and common challenges encountered with mechanical LAA exclusion. © 2018 American College of Cardiology Foundation
dc.identifier.doihttps://doi.org/10.1016/j.jacc.2018.05.048
dc.identifier.eid2-s2.0-85048927602
dc.identifier.pmid29954658
dc.identifier.urihttp://hdl.handle.net/10938/31120
dc.language.isoen
dc.publisherElsevier USA
dc.relation.ispartofJournal of the American College of Cardiology
dc.sourceScopus
dc.subjectAnticoagulants
dc.subjectAtrial fibrillation
dc.subjectCardiac surgical procedures
dc.subjectStroke
dc.subjectThromboembolism
dc.subjectAtrial appendage
dc.subjectHeart atria
dc.subjectHumans
dc.subjectRisk adjustment
dc.subjectAnticoagulant agent
dc.subjectAnastomosis leakage
dc.subjectAnticoagulation
dc.subjectCatheter ablation
dc.subjectCerebrovascular accident
dc.subjectChads2 score
dc.subjectDevice embolization
dc.subjectDialysis
dc.subjectDrug contraindication
dc.subjectHeart atrium appendage
dc.subjectHeart protection
dc.subjectHigh risk patient
dc.subjectHomeostasis
dc.subjectHuman
dc.subjectMitral valve surgery
dc.subjectPatient selection
dc.subjectPericarditis
dc.subjectPersistent atrial fibrillation
dc.subjectPostoperative complication
dc.subjectPriority journal
dc.subjectReview
dc.subjectRisk assessment
dc.subjectRisk factor
dc.subjectVisual analog scale
dc.subjectComplication
dc.subjectDevices
dc.subjectHeart atrium
dc.subjectHeart surgery
dc.subjectProcedures
dc.subjectSurgery
dc.titleCardiovascular Therapies Targeting Left Atrial Appendage
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2018-8098.pdf
Size:
1.46 MB
Format:
Adobe Portable Document Format
Download

Collections

Internal Medicine